CRISPR Therapeutics stock trades below targets despite approved gene therapy; analyst sees 85% upside potential.

CRISPR Therapeutics, owner of the first approved CRISPR-based gene therapy CASGEVY, has seen its stock trade sideways and down over the past year, currently priced at $59.03 versus an average analyst target of $87.56. Despite strong commercial progress with CASGEVY revenue up 151% year-over-year in Q2 2026 and a robust $2.56 billion cash position, the stock has underperformed due to past revenue misses and heavy cash burn. Piper Sandler analyst Edward Tenthoff is bullish, projecting an $110 price target based on expected revenue growth and new FDA approvals, implying an 86% upside. The stock's risk-reward looks favorable if CASGEVY's commercial ramp and pipeline progress materialize, though cautious investors should be mindful of volatility and potential revenue disappointments.

Following the news on CRISPR Therapeutics' mixed performance and analyst optimism, the stock trades slightly lower on Pluang at USD 58.50 as of Sep 23, 2026 19:32 WIB, down 0.90% for the day. The market cap stands at $5.71 billion, with the stock having a 52-week range between $44.34 and $76.78. Notably, Pluang investors show full buying interest with 100% buy orders and a typical hold time of 76 days.